Individuals with type 1 diabetes (T1D) have higher risks of cardiovascular disease and chronic kidney disease compared with individuals without diabetes1. Despite advances in glycemic management, 31% and 7% of…
Specialty Please choose I’m not a medical professional. Allergy and Immunology Anatomy Anesthesiology Biostatistics Cardiac/Thoracic/Vascular Surgery Cardiology Critical Care Dentistry Dermatology Diabetes and Endocrinology Emergency Medicine Epidemiology and Public Health…
CureusComparative Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors Versus Glucagon-Like Peptide-1 (GLP-1) Agonists on Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Systematic Review and Network Meta-AnalysisSodium-glucose cotransporter-2 (SGLT2) inhibitors…
Specialty Please choose I’m not a medical professional. Allergy and Immunology Anatomy Anesthesiology Biostatistics Cardiac/Thoracic/Vascular Surgery Cardiology Critical Care Dentistry Dermatology Diabetes and Endocrinology Emergency Medicine Epidemiology and Public Health…
In a multinational, retrospective cohort study of 214,442 people living with type 2 diabetes without evidence of neurodegenerative disorders, the initiation of GLP-1 RAs was associated with a 19% relative…
The Cureus Journal of Medical ScienceCardiometabolic Benefits and Risks of Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitor and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic ReviewType 2…
CureusCardiorenal Safety Markers With Injectable Glucagon-Like Peptide-1 (GLP-1) Agonists in Type 2 Diabetes: A Network Meta-AnalysisType 2 diabetes mellitus (T2DM) markedly increases the risk of cardiovascular and renal complications, emphasizing…